Comparative effectiveness of incident oral antidiabetic drugs on kidney function - Wikidata - wikimedia - TriplyDB

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

http://www.wikidata.org/entity/Q35835288

about

Effect of Metformin on Renal Function After Primary Percutaneous Coronary Intervention in Patients Without Diabetes Presenting with ST-elevation Myocardial Infarction: Data from the GIPS-III Trial.Use of cystatin C to inform metformin eligibility among adult veterans with diabetes.How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study Thiazolidinedione and Metformin Use and the Risk of Benign Prostate Hyperplasia in Veterans with Diabetes Mellitus.Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.Association of hypoglycemia with incident chronic kidney disease in patients with type 2 diabetes: a nationwide population-based study Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine.Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes.Recent trends in the prevalence of chronic kidney disease in Korean adults: Korean National Health and Nutrition Examination Survey from 1998 to 2013.Renal Disease Risk Factors Among Risk Groups Comprised of African American Women With Type 2 Diabetes: A Secondary Analysis.Peripheral arterial stiffness is independently associated with a rapid decline in estimated glomerular filtration rate in patients with type 2 diabetes Implications of different laboratory-based incident diabetic kidney disease definitions on comparative effectiveness studies.Estimating kidney function and use of oral antidiabetic drugs in elderly.Trends in the prevalence of chronic kidney disease in Korean adults: the Korean National Health and Nutrition Examination Survey from 1998 to 2009.Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney disease.Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study.Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition

P2860

Q31132421-3727FB06-9D7A-4697-AB1F-7F8C75CEE95B Q33778097-2F5F1D57-BBE2-4854-B959-EC99B71988BA Q33779315-8404A0E9-FC28-4E18-8C78-F75629088633 Q34109319-35AEDCF6-8C3B-4506-BD72-A8D311FEC017 Q34644993-5D34519A-1A2E-48D7-99A5-DD6E2DC1E09C Q35190607-E02224CD-BAEB-4740-B003-F92411ACE729 Q36038607-EDFE47A6-36BA-4F13-B54E-425223A07939 Q36064235-3F44EC32-8429-430B-8C4D-1CDE0FCA5B26 Q36152043-5C802F95-A86B-4340-B09A-2A59FF9E2689 Q36185994-36F67D6C-FCBF-45B5-82B9-F315088BF159 Q36757698-1479F2DC-D071-4607-813F-6CAD5D849B00 Q36805122-4B5EE116-DA77-46F2-A7C8-31E91A3210DF Q36952686-E6AB0D8B-2736-44A8-873F-A6FBFDF05001 Q38086611-D6529F0A-948E-4E33-88D5-16E99AD061F4 Q40053168-2D3A3C96-B5EF-462A-9D2D-7DE62D098EF2 Q40516396-76218973-9138-491F-8F3D-BA2CD811FBE9 Q40706680-BAE1341B-13B8-414A-B33E-AF77FE8B4909 Q41771923-DF8933F4-046E-43B7-B3E2-0F9CA3C6E703 Q43709731-3AD83A5E-C99A-497F-94C8-3488851E9166 Q44314307-65E881EA-61D6-45DE-BF8E-3499CD84063A Q45030630-E79737F1-FE66-4BDC-84A0-AD909321D77E Q45795381-89C252F1-9637-470B-A365-12E1D1D65ED5 Q46441179-5BEED3A3-7C94-4FE9-B5EC-D78DFA1A5EDC Q50798695-6C05AF24-5A3F-478E-8835-A7E4F14FC989 Q52639492-EC755230-F5F4-4D59-A2A8-206F8E4D3824 Q57179232-8D3ED65C-89DC-49BD-BDE5-2DD40D176429

P2860

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

http://www.wikidata.org/entity/Q35835288

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

@ast

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

@en

type

label

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

@ast

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

@en

prefLabel

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

@ast

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

@en

P1433

Q35835288-744B968D-86B5-4A99-A914-2248AC4B6D28

P1476

Q35835288-7AF9C14B-4463-456D-9B9F-3090C9C81638

P2093

Q35835288-060C36F7-2E80-4A85-85D3-2055B3A6DD48

Q35835288-07083561-615B-4097-A41E-01D286BB9691

Q35835288-5A50BFB7-3B29-4989-962B-25A75CC2F1BA

Q35835288-79049346-BCE9-4F1D-9F5A-951BF4014043

Q35835288-8F93CE19-8885-49E0-A29C-CAF2AA54A82C

Q35835288-9A15D865-05DF-4027-8F12-1304EF603EC1

Q35835288-A7C96012-0B9E-4FE9-8CF6-36C1D6A617BC

Q35835288-D33013A3-218D-49D5-8A47-7A7CBF3241FC

P2860

Q35835288-00748F0C-3E68-4A7C-B64E-5C58B44EB80D

Q35835288-0CFE3FA5-6511-467F-B3F7-51AA6670900E

Q35835288-11BDE742-1150-4746-BA8A-8794DC891567

Q35835288-15F37084-6D6F-4C48-8C97-62D0718818AF

Q35835288-182CEAAE-C20F-49DE-AFFC-F5AE5F7B948D

Q35835288-23925518-92BB-4490-B00C-6FA3B3CBD125

Q35835288-30E8F48A-9CA7-4958-A8E6-DE8A9A00A063

Q35835288-3462BDE4-0707-490A-8FD7-112508E2EE62

Q35835288-34BA0F78-FE6C-41CD-A708-29B55681A27B

Q35835288-39BC2EB5-1FE0-4FCF-8DDD-A7B04240D9C4

P2888

Q35835288-C74BCB7A-97DC-4061-BD13-27966BB3942F

P304

Q35835288-11EEAA4F-91F9-42EB-84C8-27E88013CD5F

P31

Q35835288-B85215FA-CC3D-4BEC-A28F-538CE2676BBD

P356

Q35835288-0F018FEA-EEC6-4310-8634-B7A40C21735A

P407

Q35835288-BCECD42C-1F43-4BDA-8815-DB4068B4EDF1

P433

Q35835288-E55BA4E2-DA62-4200-8201-CA08FE36E02B

P478

Q35835288-B8CEB29C-D3D9-4D0A-99E8-1045FFE6B2BD

P577

Q35835288-5874B4B2-C1BF-43B6-A6D8-26C7EFFD3BB4

P5875

Q35835288-F002A813-7885-479D-97F4-8BAFCBE38977

P698

Q35835288-F338D12C-04EC-489D-A2BD-52B159822833

P932

Q35835288-77A1A8D3-1373-4E82-8C6C-DA70B5FE167A

P356

P1433

Kidney International

P1476

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

@en

P2093

Adriana M Hung

http://www.w3.org/2001/XMLSchema#string

Carlos G Grijalva

http://www.w3.org/2001/XMLSchema#string

Christianne L Roumie

http://www.w3.org/2001/XMLSchema#string

Harvey J Murff

http://www.w3.org/2001/XMLSchema#string

Marie R Griffin

http://www.w3.org/2001/XMLSchema#string

Robert A Greevy

http://www.w3.org/2001/XMLSchema#string

T Alp Ikizler

http://www.w3.org/2001/XMLSchema#string

Xulei Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

Glucose control and vascular complications in veterans with type 2 diabetes

Excerpts from the US Renal Data System 2009 Annual Data Report.

Pharmacologic therapy for type 2 diabetes mellitus.

P2888

P304

698-706

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2011.444

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221760048

http://www.w3.org/2001/XMLSchema#string

P698

22258320

http://www.w3.org/2001/XMLSchema#string

P932

3306005

http://www.w3.org/2001/XMLSchema#string